You are on page 1of 2

CORPORATE PROFILE

A public corporation registered on the TSX Venture Exchange under the symbol APO

OUR MISSION
Acasti Pharma is a Canadian-based biopharmaceutical dedicated in the research, development and commercialization of proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment. Acasti develops first-in-class and best-in-class anti-dyslipidemic products for the prescription drugs (Rx), medical foods (MF) and over-the-counter (OTC) markets.

H I G H L I G H T S / S T R AT E G Y
To achieve regulatory submission and successfully develop CaPre through clinical Phase II; To achieve short-term revenues with Onemia; To out-license Vectos and CaPre rights.

PRODUCT PIPELINE

Over the counter

Medical Food

Prescription drug

I P a n d D I S C OV E R I E S
Parent company : Neptune Technologies & Bioressources Inc. Exclusive wordwide license from Neptune:

- Ocean Extract Proprietary extraction process - Composition of matter; - Method of use;


Patent portfolio expanded by Acasti.

MARKETS
Food - Drug - Mass - Club
Targeted Market > 50% US Population Fixed Dose Combination, Commercialization Strategic Partners

GPs, cardiologist, naturopath, chiropracters


Targeted Market > 50% US Population

Doctor prescription - > $ 30B market - $ 25B Statins - $ 1B Lavoza PRESCRIPTION DRUG

Telmed & e-commerce MEDICAL FOOD

OTC

PROOF OF CONCEPT
Precursor Neptune Clinical Study CaPreTM Pre-Clinical Study
Comparative Effects of CaPreand Lovazaon RBC Omega-3 Index (Equivalent Dosing)

Phase II clinical study

CaPre 1g Lovaza 4g CaPre vs Lovaza

OM31/G 0M3 62.85% 30.65% 105.70%

OM31/G EPA 103.26% 55.37% 86,49%

OM31/GDHA 160.62% 68.65% 133.95%

E X I T S T R AT E G Y Acasti is looking to partner for CaPre after Phase II and in the near future for Onemia and Vectos
Precedent transactions:
Year 2008 2008 Company GSK Genzyme Company Sirtris Pharma Isis Pharmaceutical Program Resvaratrol/ Natural Extract Lipid lowering agent Stage Phase 1 Phase II Transaction Value

$720M $825M

FINANCIAL FIGURES
TSX-Venture Exchange Symbol APO
R & D Investment 2008 - 2010 :

Acasti Total Investment : Cash on hand (Sept. 30, 2011) :


Shares outstanding:

$Cdn 4M $Cdn 9,4M $Cdn 9,250M 71,031,138 $Cdn 1.17 $Cdn 80,165,333
Xavier Harland

Toll Free: 1-888-221-0915 +1 403 221.0915 info@howardgroupinc.com www.howardgroupinc.com

Investor Relations
x.harland@acastipharma.com a.godin@neptunebiotech.com Neptune contact: Andr Godin

Stock price (Sept. 31, 2011): Market Capitalization:

M A N AG E M E N T A N D B OA R D O F D I R E C TO R S
MANAGEMENT
NAME
Henri Harland, MBA Tina Sampalis, MD, PhD Harlan Waksal, MD Pierre Lemieux, PhD Xavier Harland, CFA, FRM

BOARD OF DIRECTORS
POSITION
Chief Executive Officer President Executive Vice-President, Business & Scientific Affairs Chief Operation Officer Chief Financial Officer

NAME
Ronald Denis, MD Michel Chartrand Marc Lebel, PhD Martin Godbout, PhD Henri Harland, MBA

POSITION
Chairman, NTB Chief of Surgery, Sacr-Cur Hospital President, Groupe PharmEssor Prsident, Production Glaciel President, Hodran President & CEO, NTB

Neptune Administration and Accounting departments support

Head Office: 225 Promenade du Centropolis, Suite 210, Laval, (Qubec) Canada H7T 0B3 Tel.: +1 450-686-4555 Fax: +1 450-686-2505 www.acastipharma.com - info@acastipharma.com

Financial Communication Xavier Harland, Chief Financial Officer


x.harland@acastipharma.com

Scientific Communication Dr. Tina Sampalis, President


t.sampalis@acastipharma.com
This document is provided for information purposes only and does not represent an offer to sell or a sollicitation to subscribe for the securities of the society.
20111020